Pharmchem Stock Equity Positions Weight
| PCHM Stock | USD 3.10 0.00 0.00% |
PharmChem fundamentals help investors to digest information that contributes to PharmChem's financial success or failures. It also enables traders to predict the movement of PharmChem Pink Sheet. The fundamental analysis module provides a way to measure PharmChem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PharmChem pink sheet.
PharmChem |
PharmChem Company Equity Positions Weight Analysis
PharmChem's Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
More About Equity Positions Weight | All Equity Analysis
Stock Percentage | = | % of Equities | in the fund |
Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.
| Competition |
According to the company disclosure, PharmChem has an Equity Positions Weight of 0.0%. This indicator is about the same for the Health Care Providers & Services average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
PharmChem Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.0537 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | (0.06) % | |||
| Current Valuation | 17.56 K | |||
| Price To Earning | (2.30) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0006 X | |||
| Revenue | 26.45 M | |||
| Gross Profit | 5.86 M | |||
| Net Income | (2.15 M) | |||
| Cash And Equivalents | 626 K | |||
| Cash Per Share | 0.11 X | |||
| Debt To Equity | 0.37 % | |||
| Current Ratio | 0.69 X | |||
| Book Value Per Share | 1.30 X | |||
| Earnings Per Share | (0.35) X | |||
| Number Of Employees | 11 | |||
| Beta | 1.15 | |||
| Market Capitalization | 17.55 K | |||
| Total Asset | 16.66 M | |||
| Retained Earnings | (10.28 M) | |||
| Working Capital | 1.28 M | |||
| Current Asset | 6.8 M | |||
| Current Liabilities | 5.52 M | |||
| Z Score | 1.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 4.60 % | |||
| Net Asset | 16.66 M |
About PharmChem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PharmChem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmChem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmChem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in PharmChem Pink Sheet
PharmChem financial ratios help investors to determine whether PharmChem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PharmChem with respect to the benefits of owning PharmChem security.